| Non-Small Cell Lung Carcinoma
Augtyro vs Libtayo
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Augtyro vs Libtayo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLibtayo has a higher rate of injection site reactions vs Augtyro based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Libtayo but not Augtyro, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Augtyro
Libtayo
At A Glance
Oral
Once daily x14 days, then twice daily
ROS1/TRK inhibitor
IV infusion
Every 3 weeks
PD-1 inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Solid Neoplasm
- Squamous cell carcinoma of skin
- Basal cell carcinoma
- Non-Small Cell Lung Carcinoma
Dosing
Non-Small Cell Lung Carcinoma, Solid Neoplasm 160 mg orally once daily for 14 days, then increase to 160 mg twice daily, with or without food, until disease progression or unacceptable toxicity.
Squamous cell carcinoma of skin (metastatic/locally advanced) 350 mg IV infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months.
Squamous cell carcinoma of skin (adjuvant) 350 mg IV infusion every 3 weeks for 12 weeks followed by 700 mg every 6 weeks, or 350 mg every 3 weeks, until disease recurrence, unacceptable toxicity, or up to 48 weeks.
Basal cell carcinoma 350 mg IV infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months.
Non-Small Cell Lung Carcinoma 350 mg IV infusion every 3 weeks as single agent or in combination with platinum-based chemotherapy until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnea, fatigue, ataxia, cognitive impairment, muscular weakness, nausea.
Serious Pneumonia, dyspnea, pleural effusion, hypoxia.
Most common (>=15%) Fatigue, musculoskeletal pain, rash, diarrhea, anemia.
Serious Immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, exfoliative dermatologic conditions, myocarditis, neurological toxicities), infusion-related reactions, allogeneic HSCT complications, pneumonia.
Pharmacology
Repotrectinib is a kinase inhibitor of ROS1 and tropomyosin receptor tyrosine kinases (TRKA, TRKB, TRKC); fusion proteins containing these domains drive tumorigenic potential through hyperactivation of downstream signaling pathways leading to unconstrained cell proliferation.
Cemiplimab-rwlc is a recombinant human IgG4 monoclonal antibody (PD-1 inhibitor) that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Augtyro
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Libtayo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Augtyro
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Libtayo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Augtyro
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Libtayo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Augtyro.
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AugtyroView full Augtyro profile
LibtayoView full Libtayo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.